VERTEX PHARMAC. DL-,01 financial statements, including revenue, expenses, profit, and loss

The total revenue of VX1 for the last quarter is 2.28 B EUR, and it's 2.69% lower compared to the previous quarter. The net income of Q4 23 is 877.74 M EUR.